| Identification | Back Directory | [Name]
5’-[(5-Amino-6-chloro-4-pyrimidinyl)amino]-2’-fluoro-N,N-dimethyl-4’-(4-methyl-1-piperazinyl)-[1,1’-biphenyl]-4-carboxamide | [CAS]
2378768-36-4 | [Synonyms]
5’-[(5-Amino-6-chloro-4-pyrimidinyl)amino]-2’-fluoro-N,N-dimethyl-4’-(4-methyl-1-piperazinyl)-[1,1’-biphenyl]-4-carboxamide |
| Hazard Information | Back Directory | [Uses]
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research[1]. | [References]
[1] Chen W, et al. Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. J Med Chem. 2021 Jun 24;64(12):8221-8245. DOI:10.1021/acs.jmedchem.1c00091 |
|
|